Study of Lopinavir, Ritonavir, Tenofovir and Emtricitabine in HIV-Infected Antiretroviral Naïve Subjects

Phase 3 Completed 200 enrolled Abbott

RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to compare the safety, tolerability and antiviral activity between once-daily (QD) and twice-daily (BID) dosing of lopinavir/ritonavir and to further characterize the pharmacokinetics of once-daily dosing of lopinavir/ritonavir.

Timeline

Start: 2002-07
Primary completion: —
Completion: —

Publications

Podsadecki TJ, Vrijens BC, Tousset EP, Rode RA, Hanna GJ. Decreased adherence to antiretroviral therapy observed prior to transient human immunodeficiency virus type 1 viremia. J Infect Dis. 2007 Dec 15;196(12):1773-8. doi: 10.1086/523704.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Lopinavir	Other / unclassified	400 mg	—
Subject	Lopinavir	Other / unclassified	800 mg	—
Subject	Ritonavir	Other / unclassified	100 mg	—
Subject	Ritonavir	Other / unclassified	200 mg	—
Background	Tenofovir disoproxil fumarate	Small molecule	—	—
Background	emtricitabine	Other / unclassified	—	—

Study of Lopinavir, Ritonavir, Tenofovir and Emtricitabine in HIV-Infected Antiretroviral Naïve Subjects

Summary

Timeline

Publications

Drugs

Indications